DK3134124T3 - Igf-1r-antistof-lægemiddel-konjugat og dens anvendelse til behandling af kræft - Google Patents
Igf-1r-antistof-lægemiddel-konjugat og dens anvendelse til behandling af kræft Download PDFInfo
- Publication number
- DK3134124T3 DK3134124T3 DK15720045.2T DK15720045T DK3134124T3 DK 3134124 T3 DK3134124 T3 DK 3134124T3 DK 15720045 T DK15720045 T DK 15720045T DK 3134124 T3 DK3134124 T3 DK 3134124T3
- Authority
- DK
- Denmark
- Prior art keywords
- igf
- antibody
- cancer
- treatment
- application
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14305620 | 2014-04-25 | ||
| PCT/EP2015/059045 WO2015162291A1 (en) | 2014-04-25 | 2015-04-27 | Igf-1r antibody-drug-conjugate and its use for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3134124T3 true DK3134124T3 (da) | 2019-05-06 |
Family
ID=50630736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15720045.2T DK3134124T3 (da) | 2014-04-25 | 2015-04-27 | Igf-1r-antistof-lægemiddel-konjugat og dens anvendelse til behandling af kræft |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US10633448B2 (da) |
| EP (2) | EP3134124B1 (da) |
| JP (1) | JP6258523B2 (da) |
| KR (1) | KR101795984B1 (da) |
| CN (1) | CN106456800B (da) |
| AU (1) | AU2015250759B2 (da) |
| BR (1) | BR112016024619A2 (da) |
| CA (1) | CA2946469C (da) |
| CY (1) | CY1121783T1 (da) |
| DK (1) | DK3134124T3 (da) |
| ES (1) | ES2727103T3 (da) |
| HR (1) | HRP20190888T8 (da) |
| HU (1) | HUE044862T2 (da) |
| IL (1) | IL248455B (da) |
| LT (1) | LT3134124T (da) |
| MA (2) | MA47811A (da) |
| MX (1) | MX2016013704A (da) |
| MY (1) | MY186711A (da) |
| PL (1) | PL3134124T3 (da) |
| PT (1) | PT3134124T (da) |
| RS (1) | RS58742B1 (da) |
| RU (1) | RU2692563C2 (da) |
| SA (1) | SA516380120B1 (da) |
| SI (1) | SI3134124T1 (da) |
| TN (1) | TN2016000472A1 (da) |
| UA (1) | UA120364C2 (da) |
| WO (1) | WO2015162291A1 (da) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA47811A (fr) * | 2014-04-25 | 2019-06-19 | Pf Medicament | Kit comprenant un conjugué anticorps-médicament igf-1r et son utilisation pour le traitement du cancer |
| JP6968790B2 (ja) | 2015-10-26 | 2021-11-17 | ピエール、ファーブル、メディカマン | Ｉｇｆ−１ｒ発現癌の処置のための組成物 |
| EP3427055A1 (en) | 2016-03-07 | 2019-01-16 | Pierre Fabre Medicament | A new universal method to capture and analyze adcs for characterization of drug distribution and the drug-to-antibody ratio in biological samples |
| CN113453724A (zh) | 2018-09-27 | 2021-09-28 | 皮埃尔法布雷医药公司 | 基于磺酰基马来酰亚胺的连接子和相应的偶联物 |
| CN111327570B (zh) | 2018-12-14 | 2021-09-17 | 北京京东尚科信息技术有限公司 | 验证方法、装置和计算机可读存储介质 |
| EP3735991A1 (fr) * | 2019-05-06 | 2020-11-11 | Pierre Fabre Medicament | Adc pour un traitement concomitant ou postérieur au docétaxel |
| EP3909612A1 (en) | 2020-05-12 | 2021-11-17 | Life Science Inkubator Betriebs GmbH & Co. KG | Composition of nanoparticles |
| WO2023240223A2 (en) * | 2022-06-10 | 2023-12-14 | Acelyrin, Inc. | Anti-igf-1r antibody compositions |
| EP4353220A1 (en) | 2022-10-12 | 2024-04-17 | Pierre Fabre Medicament | Use of a liquid aqueous composition for solubilization and stabilization of an antibody-drug conjugate |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| EP0731106B1 (en) | 1993-10-01 | 2004-11-17 | Teikoku Hormone Mfg. Co., Ltd. | Dolastatin derivatives |
| US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| US20050276812A1 (en) * | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Antibody-drug conjugates and methods |
| NZ580115A (en) | 2004-09-23 | 2010-10-29 | Genentech Inc | Cysteine engineered antibody light chains and conjugates |
| BRPI0617546A2 (pt) | 2005-09-26 | 2011-07-26 | Medarex Inc | conjugado de fÁrmaco-anticorpo, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula de tumor, mÉtodo para retardar ou interromper o crescimento de um tumor em um sujeito mamÍfero e composto |
| TW200833711A (en) | 2006-12-22 | 2008-08-16 | Genentech Inc | Antibodies to insulin-like growth factor receptor |
| AR065803A1 (es) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento |
| EP2144628B1 (en) | 2007-05-08 | 2012-10-17 | Genentech, Inc. | Cysteine engineered anti-muc16 antibodies and antibody drug conjugates |
| MX2010003718A (es) | 2007-10-19 | 2010-04-21 | Genentech Inc | Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo. |
| EP2276509B1 (en) | 2008-04-11 | 2016-06-15 | Seattle Genetics, Inc. | Detection and tratment of pancreatic, ovarian and other cancers |
| EP2403524A4 (en) | 2009-03-06 | 2012-09-26 | Agensys Inc | CONJUGATES ANTIBODY-DRUG (ADC) BINDING PROTEINS 24P4C12 |
| WO2010146059A2 (en) * | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
| TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| PE20130342A1 (es) | 2010-04-15 | 2013-04-20 | Spirogen Sarl | Pirrolobenzodiacepinas y conjugados de las mismas |
| EP2579887B1 (de) | 2010-06-10 | 2014-11-12 | Seattle Genetics, Inc. | Neue auristatin-derivate und ihre verwendung |
| ES2553874T3 (es) | 2010-09-29 | 2015-12-14 | Seattle Genetics, Inc. | N-Carboxialquil-auristatinas y su uso |
| ES2730941T7 (es) * | 2010-10-22 | 2020-05-27 | Seattle Genetics Inc | Efectos sinérgicos entre los conjugados de conjugados anticuerpo-fármaco a base de auristatina e inhibidores de la ruta PI3K-AKT-mTOR |
| EP2635310A2 (en) | 2010-11-05 | 2013-09-11 | Rinat Neuroscience Corp. | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| CN103764667B (zh) | 2011-03-16 | 2017-06-20 | 西雅图基因公司 | N‑羧烷基耳他汀类及其应用 |
| US9150644B2 (en) | 2011-04-12 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II |
| EP3170821B1 (en) | 2011-05-27 | 2021-09-15 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
| JP6581774B2 (ja) | 2011-05-27 | 2019-09-25 | アンブルックス, インコーポレイテッドAmbrx, Inc. | 非天然アミノ酸結合ドラスタチン誘導体を含有する化合物またはその化合物の溶媒和物、およびドラスタチンアナログを誘導体化するための方法 |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| AU2013270686B2 (en) | 2012-06-07 | 2016-11-10 | Ambrx, Inc. | Prostate-specific membrane antigen antibody drug conjugates |
| EP2861262B1 (en) | 2012-06-19 | 2018-11-28 | Ambrx, Inc. | Anti-cd70 antibody drug conjugates |
| US20140017265A1 (en) | 2012-07-05 | 2014-01-16 | Mersana Therapeutics, Inc. | Terminally Modified Polymers and Conjugates Thereof |
| CN104781281A (zh) | 2012-08-14 | 2015-07-15 | 安吉奥开米公司 | 包含抗体部分、穿过血脑屏障的多肽和细胞毒素的结合物 |
| EP2934596A1 (en) | 2012-12-21 | 2015-10-28 | Glykos Finland Oy | Linker-payload molecule conjugates |
| FR3005051A1 (fr) | 2013-04-25 | 2014-10-31 | Pf Medicament | Derives de la dolastatine 10 et d'auristatines |
| MA47811A (fr) * | 2014-04-25 | 2019-06-19 | Pf Medicament | Kit comprenant un conjugué anticorps-médicament igf-1r et son utilisation pour le traitement du cancer |
| RU2685259C2 (ru) | 2014-04-25 | 2019-04-17 | Пьер Фабр Медикамент | Конъюгат антитела и лекарственного средства и его применение для лечения рака |
| CN112851808A (zh) * | 2014-04-25 | 2021-05-28 | 皮埃尔法布雷医药公司 | Igf-1r抗体及其作为定位载体用于治疗癌症的用途 |
| JP6968790B2 (ja) * | 2015-10-26 | 2021-11-17 | ピエール、ファーブル、メディカマン | Ｉｇｆ−１ｒ発現癌の処置のための組成物 |
-
2015
- 2015-04-27 MA MA047811A patent/MA47811A/fr unknown
- 2015-04-27 CA CA2946469A patent/CA2946469C/en active Active
- 2015-04-27 RU RU2016145444A patent/RU2692563C2/ru active
- 2015-04-27 MX MX2016013704A patent/MX2016013704A/es active IP Right Grant
- 2015-04-27 HU HUE15720045 patent/HUE044862T2/hu unknown
- 2015-04-27 US US15/306,351 patent/US10633448B2/en active Active
- 2015-04-27 EP EP15720045.2A patent/EP3134124B1/en active Active
- 2015-04-27 MY MYPI2016703874A patent/MY186711A/en unknown
- 2015-04-27 TN TN2016000472A patent/TN2016000472A1/en unknown
- 2015-04-27 JP JP2016564149A patent/JP6258523B2/ja active Active
- 2015-04-27 KR KR1020167031683A patent/KR101795984B1/ko active IP Right Grant
- 2015-04-27 BR BR112016024619A patent/BR112016024619A2/pt not_active Application Discontinuation
- 2015-04-27 PT PT15720045T patent/PT3134124T/pt unknown
- 2015-04-27 LT LTEP15720045.2T patent/LT3134124T/lt unknown
- 2015-04-27 DK DK15720045.2T patent/DK3134124T3/da active
- 2015-04-27 SI SI201530751T patent/SI3134124T1/sl unknown
- 2015-04-27 RS RS20190615A patent/RS58742B1/sr unknown
- 2015-04-27 PL PL15720045T patent/PL3134124T3/pl unknown
- 2015-04-27 EP EP19154902.1A patent/EP3498301A1/en not_active Withdrawn
- 2015-04-27 UA UAA201611833A patent/UA120364C2/uk unknown
- 2015-04-27 CN CN201580033382.0A patent/CN106456800B/zh active Active
- 2015-04-27 WO PCT/EP2015/059045 patent/WO2015162291A1/en active Application Filing
- 2015-04-27 ES ES15720045T patent/ES2727103T3/es active Active
- 2015-04-27 MA MA39909A patent/MA39909B1/fr unknown
- 2015-04-27 AU AU2015250759A patent/AU2015250759B2/en not_active Ceased
-
2016
- 2016-10-23 IL IL248455A patent/IL248455B/en active IP Right Grant
- 2016-10-23 SA SA516380120A patent/SA516380120B1/ar unknown
-
2019
- 2019-05-15 CY CY20191100523T patent/CY1121783T1/el unknown
- 2019-05-15 HR HRP20190888TT patent/HRP20190888T8/hr unknown
-
2020
- 2020-02-26 US US16/801,491 patent/US11661457B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3288581T3 (da) | Fremgangsmåde til behandling af cancer | |
| DK3558997T3 (da) | Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer | |
| DK3166976T3 (da) | Anti-pd-l1-kombinationer til behandling af tumorer | |
| DK3331915T3 (da) | Immun-checkpoint-inhibitorer til anvendelse til behandling af blodbårne cancere | |
| DK3377516T3 (da) | Sammensætning til behandling af cancer | |
| DK3178849T3 (da) | Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer | |
| DK3212233T3 (da) | Kombinationsterapi til behandling af sygdom | |
| DK3189082T3 (da) | Anti-pd-l1-konjugater til behandling af tumorer | |
| DK3134530T3 (da) | Behandling af hyperbilirubinæmi | |
| DK3317284T3 (da) | Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK3126394T3 (da) | Anti-OX40-antistoffer og fremgangsmåder til anvendelse | |
| DK3594238T3 (da) | Antistofsammensætninger til tumorbehandling | |
| DK3277842T3 (da) | Fremgangsmåder til at behandle kræftpatienter med farnesyl-transferase-inhibitorer | |
| DK3122358T3 (da) | Kombinationer af fgfr- og cmet-hæmmere til cancerbehandling | |
| DK3134124T3 (da) | Igf-1r-antistof-lægemiddel-konjugat og dens anvendelse til behandling af kræft | |
| BR112017011771A2 (pt) | métodos e composições para o tratamento de câncer | |
| DK3148529T3 (da) | Forbindelser til behandling af hjernecancer | |
| DK3209696T3 (da) | Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom | |
| DK3144001T3 (da) | Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf | |
| DK3200815T3 (da) | Fremgangsmåder og sammensætninger til behandling af cancer | |
| DK3458052T3 (da) | Kombinationsbehandling af cancer | |
| DK3302063T3 (da) | Fremgangsmåde til stimulering af frø | |
| DK3265087T3 (da) | Fremgangsmåde til behandling med tradipitant | |
| DK3261726T3 (da) | Sammensætning til behandling af acne |